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Millions of people are struggling with addictions to smoking, drinking and taking drugs, 
but the search for new medications to help them quit remains elusive. Here’s why. 
 
Scientists may seem as if they can do a lot, like 
genetic engineering or controlling neurons with 
light, but cures for many conditions remain 
elusive. One such condition is addiction, which 
involves compulsive drug-taking over a long 
period of time that interferes with a person’s 
ability to lead a normal life. Drug addiction has 
many negative effects on the health of the drug 
user and causes problems for other people at 
home, at work and through increased crime. 
Despite the problems addiction creates for an 
individual and their community, most drugs of 
addiction have no, or only modestly effective, 
anti-craving medications available. The result is 
that most patients will relapse even if they are 
given the best available counselling and medical 
treatment. Demand for anti-craving medicines is 
so strong that patients will turn to miracle cures 
that are more hype than substance, such as 
baclofen, a drug which became popular in France 
after a doctor wrote a book about using it to treat 
his own alcohol addiction.  
However, as courageous as testing new treatments 
on yourself is, most scientists working to develop 
cures have a lot more hoops to jump through. 
The first step is to find a biological target that a 
new medicine can work on. For addiction, these 
are usually the signalling molecules in the brain, 
such as GABA which is mimicked by baclofen, or 
the brain’s natural opioids which are blocked by 
naltrexone to treat alcohol addiction.  
One potential target that has been in preclinical 
testing for over a decade is the orexin system. The 
orexins are small signalling proteins in the brain 
that were discovered in 1998 to regulate 
wakefulness and feeding. Since 2005, it has been 
shown that the orexins are involved in how 
animals experience the pleasurable effects of 
various drugs of abuse, such as morphine, cocaine 
and alcohol.  
Rats on Drugs 
Of course, scientists cannot just take an 
experimental drug and stick it in human addicts 
to see what it does, especially if no one knows if 
the experimental drug has a reasonable chance of 
helping. So we have to start by doing preclinical 
testing with laboratory animals, usually rats or 
mice.  
Addiction is a complex disorder and there are lots 
of ways that this is modelled using animals. Early 
studies tested the way orexins are involved in how 
the brain processes the drug ‘high’. For example, 
if a mouse gets pleasure from morphine or 
cocaine, it will like spending time in places that 
remind it of those drugs. Activating orexin 
neurons increases this preference, suggesting that 
they are involved in those pleasurable experiences. 
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Another way is to just let rats take as much drug 
as they want. In these experiments, rats learn to 
do something, like press a lever, to get a few drops 
of alcohol, a bit of nicotine or a tasty food pellet. 
The advantage of this approach is that the rat is 
only taking drugs it wants to take, just like how 
humans only take drugs they want to take. Using 
this approach, Australian scientists at the Florey 
Institute of Neuroscience and Mental Health 
were the first to show that the orexin system 
might be involved in alcohol addiction. 
Rats can also experience cycles of rehabilitation 
and relapse. During the rat-rehab phase, lever 
presses do not produce any drug no matter how 
hard the rat tries. Over time, the number of lever 
presses they make decreases, but during rat-
relapse it can be rekindled by the same kinds of 
things that trigger relapse in humans – cues or 
places that are associated with the drug, stress, the 
drug itself or simply the passage of time. 
Does it Really Work? 
Once a potential target for a new medicine has 
been identified, it needs to be tested in different 
ways to see if it will really work and, if it does, 
how it works. Together with my supervisors and 
colleagues, I have spent the past 5 years testing the 
effects of experimental drugs that block orexin 
signals in rats that are taking, or trying to take, 
alcohol, nicotine or junk food. But our results, 
like the disorder of addiction, are a bit 
complicated. 
Neurons that receive orexin signals actually 
recognise orexin proteins with two different 
receptors. Most of the time the orexin signal will 
do the same thing at either receptor, but there are 
some subtle differences. For example, using 
experimental drugs that block orexin signals at 
one receptor reduced both the amount of alcohol 
consumed and the severity of rat-relapse in rats 
with a genetic predisposition to alcohol 
consumption. But when we tested a drug that 
blocked the other orexin receptor, only the 
amount of alcohol consumed decreased and rat-
relapse was unaffected. Importantly, these drugs 
worked when injected directly into the reward 
circuitry of the brain, suggesting that orexins are 
involved in driving motivation. 
Different drugs of addiction also have different 
effects on the brain, so it’s important to look at 
more than one. Legal drugs of abuse (alcohol and 
nicotine) cause just as much harm, if not more, 
than illegal drugs, so we also studied the effect of 
blocking orexin signalling in rats taking nicotine. 
We found that experimental drugs that blocked 
both orexin receptors had only a very small effect 
on rat-relapse and only if the rats had spent more 
than a month taking nicotine. However, the 
effect was far too small to recommend targeting 
orexins for smoking. 
Addiction scientists dream of a new medication 
able to reduce craving for addictive drugs while 
not affecting normal motivation. Addictive drugs 
work through similar psychological processes and 
brain circuits as things that normally motivate 
people and animals, like food. Current 
medications, like naltrexone, are not very good at 
this but our studies suggest that an orexin 
medication might be able to. 
Junk food is a great motivator that is not an 
addictive drug, so we also tested the effect of 
experimental anti-orexin drugs in rats with a taste 
for food pellets high in fat and sugar. We tested 
four different experimental drugs which blocked 
one or both of the orexin receptors and found no 
effect on how much food the rats would 
consume. Even when we looked in the brains of 
our rats for signs of orexin neuron activation 
during rat-relapse, we found that their activity 
was not specifically related to cues that were 
associated with junk food. It seems as if the orexin 
system is picky about when it gets involved in 
motivation, which can be a good thing if it is ever 
used to treat addiction.  
Miracle Cures and Dead Ends 
These results do not point to a simple answer for 
whether we should use anti-orexin drugs to treat 
addiction. In some cases, they may be effective 
but it will depend on the addictive drug, the 
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patient and the aim of treatment. For example, a 
medicine which targets orexins might work for 
patients with a family history of alcohol 
addiction, like it did for rats with a genetic 
predisposition to alcohol consumption. 
However, this might not work for everyone 
because in other studies we did not find any effect 
of blocking orexin signals in rats with no genetic 
predispositions. 
Other researchers have had much better luck with 
anti-orexin drugs and cocaine. Scientists at the 
University of Texas Health Science Center 
registered a clinical trial in 2016 to begin testing 
suvorexant, an insomnia medication that blocks 
orexin signals, in patients with cocaine addiction. 
There are also other clinical trials underway 
testing medicines that target systems other than 
the orexins, such as glutamate and GABA. The 
glutamate and GABA systems are the brain’s 
main way of controlling its level of excitability, 
with glutamate increasing excitability and GABA 
decreasing excitability. Topiramate targets both 
by mimicking GABA and blocking glutamate 
signals and is being trialled for alcohol and 
cocaine addiction, while N-acetyl cysteine blocks 
glutamate signalling and is being tested against 
cannabis, alcohol, smoking and cocaine. 
Meanwhile, the miracle cure of baclofen is losing 
its shine. In France, baclofen overdoses occur in 
patients with alcohol addiction on a weekly basis, 
nearly 75% of which are intentional, and its side-
effects are involved in hundreds of adverse drug 
reactions each year. One recently reported clinical 
trial sponsored by the pharmaceutical company 
Ethypharm found approximately 90% of patients 
relapsed, even if given baclofen.  
Careful research at preclinical stages can help 
prevent ineffective and potentially unsafe drugs 
from making their way into the clinic. Progress is 
slow because addiction has many psychological 
and neural aspects, like motivation, reward, stress 
and craving. For every potential biological target, 
of which the orexins are just one, this process of 
preclinical testing has to happen again. While 
trying to find cures we run into many dead ends, 
but new medications in clinical trials give hope 
that better treatments will eventually become 
available. Just don’t rush out for the miracle 
cures. 
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